Zoetis' Low Valuation: A Buying Opportunity?

Zoetis, a leading animal health company, is currently trading at a discounted P/E ratio of 19, its lowest in a decade. The primary reason for this is the controversy surrounding their top-selling osteoarthritis drug, Librela, due to reported serious side effects. Despite the 16% sales drop in 2025, Zoetis remains diversified across livestock and companion animals, with Librela and Solensia accounting for only 6% of their revenue. The companys growth prospects are promising, with a strong pipeline and tailwinds from rising pet ownership and meat demand in emerging markets. Wall Street predicts a 9.3% annual earnings growth, suggesting the current valuation could rebound to its usual high levels. Support the show:Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/1032cfaeabcd0381